Novel biomarkers for early targeted and individualized treatment in Juvenile Idiopathic Arthritis | Zendy

Artemis Koutsonikoli | Zendy; Άννα Ταπάρκου | Zendy; Polyxeni Pratsidou-Gkertsi | Zendy; Vasiliki Sgouropoulou | Zendy; Theodoros Dimitroulas | Zendy; Maria Trachana | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Novel biomarkers for early targeted and individualized treatment in Juvenile Idiopathic Arthritis

Author(s) -

Artemis Koutsonikoli,

Άννα Ταπάρκου,

Polyxeni Pratsidou-Gkertsi,

Vasiliki Sgouropoulou,

Theodoros Dimitroulas,

Maria Trachana

Publication year - 2020

Publication title -

mediterranean journal of rheumatology

Language(s) - English

Resource type - Journals

ISSN - 2529-198X

DOI - 10.31138/mjr.31.2.230

Subject(s) - cd19 , synovial fluid , medicine , arthritis , immunology , flow cytometry , cd8 , regulatory b cells , immune system , inflammation , pathology , interleukin 10 , alternative medicine , osteoarthritis

The programmed cell death protein-1 (PD-1) and its ligands (PD-L 1 and 2) suppress immune responses, thus promoting self-tolerance. Among the immunomodulatory cells, acting through the PD-1 pathway, are the B-regulatory cells (Bregs). The role of the PD-1 pathway in Juvenile Idiopathic Arthritis (JIA) has not been adequately studied.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research